Bioventus Inc Cl A (BVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 51,238 | 42,164 | 32,910 | 22,802 | 41,582 |
| Receivables | 128,303 | 130,404 | 132,367 | 118,082 | 127,393 |
| Inventories | 82,236 | 96,273 | 96,465 | 94,045 | 92,475 |
| TOTAL | $272,842 | $280,901 | $275,203 | $249,367 | $275,610 |
| Non-Current Assets | |||||
| PPE Net | 21,899 | 22,983 | 24,512 | 25,722 | 27,012 |
| Investments And Advances | 2,293 | 2,274 | 1,687 | 1,756 | 1,892 |
| Intangibles | 375,881 | 384,860 | 394,416 | 403,193 | 412,191 |
| Other Non-Current Assets | 10,644 | 10,575 | 10,970 | 11,376 | 11,251 |
| TOTAL | $410,717 | $420,692 | $431,585 | $442,047 | $452,346 |
| Total Assets | $683,559 | $701,593 | $706,788 | $691,414 | $727,956 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 15,000 | 11,250 | 43,358 | 37,339 | 27,339 |
| Accounts payable and accrued liabilities | 10,928 | 26,649 | 24,245 | 19,197 | 23,690 |
| Accrued Expenses | 130,242 | 119,446 | 113,666 | 103,283 | 135,879 |
| Other current liabilities | 4,210 | 4,407 | 4,411 | 14,932 | 23,490 |
| TOTAL | $160,380 | $161,752 | $185,680 | $174,751 | $210,398 |
| Non-Current Liabilities | |||||
| Long Term Debt | 278,951 | 311,334 | 297,880 | 308,593 | 308,288 |
| Other Non-Current Liabilities | 12,785 | 19,615 | 19,465 | 22,669 | 23,317 |
| TOTAL | $294,732 | $332,586 | $319,809 | $331,184 | $331,954 |
| Total Liabilities | $455,112 | $494,338 | $505,489 | $505,935 | $542,352 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 83,155 | 82,763 | 82,679 | 82,144 | 81,944 |
| Common Shares | 83 | 83 | 83 | 82 | 82 |
| Retained earnings | -334,929 | -349,684 | -352,839 | -360,298 | -357,661 |
| Other shareholders' equity | 42,442 | 39,322 | 39,283 | 35,273 | 35,091 |
| TOTAL | $228,447 | $207,255 | $201,299 | $185,479 | $185,604 |
| Total Liabilities And Equity | $683,559 | $701,593 | $706,788 | $691,414 | $727,956 |